PHAR Pharming Corp: רווח נקי למניה ב-12 החודשים האחרונים

Pharming Group N.V. (PHAR) specializes in the therapy of orphan immune pathologies, creating life-saving solutions for patients. Its own Dutch protein synthesis facilities guarantee uninterrupted production. High demand for its core drug ensures a stable cash flow. The rolling annual EPS YoY trend demonstrates earnings resilience, while the value of 2244.10 aligns with the current metric.
PHAR (Pharming): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To objectively evaluate the issuer, it is essential for the manager to track the annual earnings per share (EPS) dynamics over the last 12 months, which reveals the actual pace of business scaling. Analyzing the 12-month YoY EPS trend allows for a comparison of Pharming Group N.V. (PHAR) financial efficiency against the costs of developing recombinant proteins for the therapy of rare genetic pathologies.